Morepen Laboratories Sets Sail for Dubai: Pharma Giant Unleashes Global Ambitions in the Desert Oasis

In a strategic move to accelerate its global expansion, Morepen Laboratories Limited has officially incorporated a wholly owned subsidiary, Morepen Labs – FZCO, in the Dubai Free Zone jurisdiction. This is a milestone in the company's global expansion strategy and positions Morepen to tap into bigger pharma markets worldwide.

 

Key Points

Formal Registration: Morepen Labs – FZCO was formally registered on June 18, 2025, in Dubai Free Zone, United Arab Emirates, as per the company's regulatory filing.

 

Ownership Structure: The new company is formed with a capital of AED 50,000, split into 5,000 ordinary shares of AED 10 each. The company is 100% owned by Morepen Laboratories, hence retaining full control over the subsidiary's operations.

 

Area of Operations: The Dubai subsidiary will be involved in the export of pharmaceuticals and medicines from the UAE, as part of Morepen's core business and global trade strategy.

 

No Promoter Interest: The company informed that there is no direct interest of the promoter or the promoter group in the new company, which is a group entity of the holding company.

 

Regulatory Simplification: The acquisition did not need any regulatory or government approvals and was settled through cash consideration, making the process simpler.

 

Strategic Significance: Such a move would most likely increase the international penetration of Morepen Laboratories, with better access to global pharma markets and becoming a market leader in the sector.

 

Industry Perspective:

Morepen Labs – FZCO's presence in Dubai has been viewed as a progressive step to leverage the city's role as a world-class international business hub so that Morepen can serve global customers in the right manner and expand its export business. 

 

Source: Business Upturn